Gardiquimod

Gardiquimod is an imidazoline TLR7/8 agonist. Gardiquimod inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs) . Gardiquimod specifically activates TLR7 at concentrations below 10 μM.

Product Specifications

CAS Number

[1020412-43-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/gardiquimod.html

Concentration

10mM

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC(C)(C)CN1C(CNCC)=NC2=C1C3=CC=CC=C3N=C2N

Molecular Formula

C17H23N5O

Molecular Weight

313.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Buitendijk M, et al. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013 Jun;29 (6) :907-18.|[2]Zhou Z, et al. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015 Dec 28;369 (2) :298-306.